Cic edizioni internazionali
Clinical Cases in mineral and bone metabolism

The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer

Original Article, 35 - 39
doi: 10.11138/ccmbm/2017.14.1.035
Tag this article
Abstract
Full text PDF
Introduction. There are controversial results in the risk of atrial fibrillation as well as arrhythmogenic potential of bisphosphonates.
Method. 37 patients and 40 healthy controls were evaluated prospectively with regard to the cardiac side effects related to the use of zoledronic acid (ZA) and its effects on electrocardiography (ECG) parameters.
Result. As the basal ECG results of the patients diagnosed with cancer compared with the control group, it was determined that QT maximum was significantly lower, QT minimum was significantly higher. However; it was determined that QT disp, P max, P min, and P disp values were not significantly different. There was no statistically significant difference in P max, P min, P disp, QT max, QT min, QT disp values of the ECG parameters measured from cancer patients, before and 60 minutes after ZA therapy.
Conclusion. There were no significant alterations in ECG in the acute period, indicated that ZA had no arrhythmia potential in the early period in patients with no underlying cardiac disease. However: patients receiving ZA should be monitored more closely because of the risk of arrhythmia which may ensue due to hypocalcemia, hypomagnesemia, or other chemotherapeutics.

Vol. XIV (No. 1) 2017 January - April

  1. From the Editor-in-Chief
    Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.011
  2. Low-dose diclofenac in patients with fragility fractures
    Vannucci L., Fossi C., Gronchi G., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.015
  3. Vitamin D levels and their impact on mineral metabolism in HIV infected patients: an exploratory study
    Mastaglia S., Watson D., Bello N., Fridman V., Stecher D., Oliveri B.
    doi: 10.11138/ccmbm/2017.14.1.018
  4. New quantitative ultrasound techniques for bone analysis at the distal radius in hip fracture cases: differences between femoral neck and trochanteric fractures
    Horii M., Fujiwara H., Sakai R., Sawada K., Mikami Y, Toyama S., Ozaki E., Kuriyama N., Kurokawa M., Kubo T.
    doi: 10.11138/ccmbm/2017.14.1.023
  5. Use of teriparatide off-label: our experience and review of literature
    Ciurlia E., Tranquilli Leali P., Doria C.
    doi: 10.11138/ccmbm/2017.14.1.028
  6. The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer
    Demirtas D., Bilir C., Demirtas A.O., Engin H.
    doi: 10.11138/ccmbm/2017.14.1.035
  7. A comparison of two fixation methods for femoral trochanteric fractures: a new generation intramedullary system vs sliding hip screw
    Carulli C., Piacentini F., Paoli T., Civinini R., Innocenti M.
    doi: 10.11138/ccmbm/2017.14.1.041
  8. The use of cholecalciferol in patients with hip fracture
    Cianferotti L., Parri S., Gronchi G., Civinini R., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.048
  9. Evaluation of bone microstructure in CRPS-affected upper limbs by HR-pQCT
    Mussawy H., Schmidt T., Rolvien T., Rüther W., Amling M.
    doi: 10.11138/ccmbm/2017.14.1.054
  10. Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update
    Marini F., Cianferotti L., Giusti F., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.060
  11. Bone health in menopausal women: a role for General Practitioners
    Michieli R., Musto M.
    doi: 10.11138/ccmbm/2017.14.1.071
  12. Legg-Calvé-Perthes disease: classifications and prognostic factors
    Rampal V., Clément J.-L., Solla F.
    doi: 10.11138/ccmbm/2017.14.1.074
  13. Transient osteoporosis of the hip with a contralateral delayed involvement: a case report
    Iannò B., De Gori M., Familiari F., Pugliese T., Gasparini G.
    doi: 10.11138/ccmbm/2017.14.1.083
  14. A case report: hypercalcemia due to vitamin supplementation in a patient with neurofibromatosis
    Crone M., Fogarty K.
    doi: 10.11138/ccmbm/2017.14.1.087
  15. Is this a seizure?
    Franceschet G., Mazzucato M., Censi S., Simmini S., Boscaro M., Camozzi V.
    doi: 10.11138/ccmbm/2017.14.1.089
  16. Histological and micro Computed Tomography analysis of a femoral stress fracture associated with prolonged bisphosphonate use
    Somford M.P., van Ruijven L.J., Kloen P., Bakker A.D.
    doi: 10.11138/ccmbm/2017.14.1.092
  17. Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider?
    De Keukeleire S., Muylle K., Tsoumalis G., Vermeulen S., Vogelaers D.
    doi: 10.11138/ccmbm/2017.14.1.097
  18. Acute severe diarrhoea and hyponatremia after zoledronic acid infusion: an acute phase reaction
    Shafi Kuchay M., Farooqui K.J., Mithal A.
    doi: 10.11138/ccmbm/2017.14.1.101
  19. LoCa LoPa myelopathy: is prevention better than cure?
    Pandita K.K., Razdan S., Pandita S.
    doi: 10.11138/ccmbm/2017.14.1.105
Last Viewed articles: la lista degli ultimi x visitati.
  1. The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer
    Demirtas D., Bilir C., Demirtas A.O., Engin H.
    doi: 10.11138/ccmbm/2017.14.1.035
credits